Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D08QHS
|
|||
| Former ID |
DCL000105
|
|||
| Drug Name |
DG041
|
|||
| Synonyms |
DTSI; D-000151746; DG-041
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Peripheral vascular disease [ICD-11: BD4Z; ICD-10: I73.9; ICD-9: 443.9] | Discontinued in Phase 2 | [1], [2] | |
| Company |
DeCODE genetics
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C23H15Cl4FN2O3S2
|
|||
| Canonical SMILES |
CC1=CN(C2=C(C=C(C=C12)F)C=CC(=O)NS(=O)(=O)C3=CC(=C(S3)Cl)Cl)CC4=C(C=C(C=C4)Cl)Cl
|
|||
| InChI |
1S/C23H15Cl4FN2O3S2/c1-12-10-30(11-14-2-4-15(24)7-18(14)25)22-13(6-16(28)8-17(12)22)3-5-20(31)29-35(32,33)21-9-19(26)23(27)34-21/h2-10H,11H2,1H3,(H,29,31)/b5-3+
|
|||
| InChIKey |
BFBTVZNKWXWKNZ-HWKANZROSA-N
|
|||
| CAS Number |
CAS 861238-35-9
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Prostaglandin E2 receptor EP3 (PTGER3) | Target Info | Antagonist | [3], [4] |
| KEGG Pathway | Calcium signaling pathway | |||
| cAMP signaling pathway | ||||
| Neuroactive ligand-receptor interaction | ||||
| Regulation of lipolysis in adipocytes | ||||
| Pathways in cancer | ||||
| NetPath Pathway | IL2 Signaling Pathway | |||
| Reactome | Prostanoid ligand receptors | |||
| G alpha (i) signalling events | ||||
| WikiPathways | Prostaglandin Synthesis and Regulation | |||
| GPCRs, Class A Rhodopsin-like | ||||
| Small Ligand GPCRs | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5822). | |||
| REF 2 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800015910) | |||
| REF 3 | BAY x 1005 attenuates atherosclerosis in apoE/LDLR - double knockout mice. J Physiol Pharmacol. 2007 Sep;58(3):583-8. | |||
| REF 4 | Effects of a 5-lipoxygenase-activating protein inhibitor on biomarkers associated with risk of myocardial infarction: a randomized trial. JAMA. 2005 May 11;293(18):2245-56. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.